CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-10 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 | −5,124 | $10.35 | $53K | 247,926 |
| 2026-02-01 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes | −5,267 | $11.16 | $59K | 253,050 |
| 2026-02-01 | Christmas Patrick J. Chief Strategy & Legal Officer | Shares withheld for taxes | −4,700 | $11.16 | $52K | 210,667 |
| 2026-01-27 | Mills Kenneth T. Director | Option exercise | +225,000 | $13.09 | $2.9M | 707,871 |
| 2026-01-27 | Mills Kenneth T. Director | Shares withheld for taxes | −221,753 | $13.41 | $3.0M | 486,118 |
| 2026-01-27 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) | −225,000 | 225,000 | ||
| 2026-01-06 | Malzahn Craig Chief Technology Officer | Grant or award | +65,847 | 82,194 | ||
| 2026-01-06 | Malzahn Craig Chief Technology Officer | Grant or award · Stock Options (Right to buy) | +35,402 | 35,402 | ||
| 2026-01-06 | Chan Mitchell Chief Financial Officer | Grant or award | +73,749 | 127,717 | ||
| 2026-01-06 | Chan Mitchell Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +39,650 | 39,650 | ||
| 2026-01-06 | PAKOLA STEVE Chief Medical Officer | Grant or award | +65,847 | 258,317 | ||
| 2026-01-06 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Options (Right to buy) | +35,402 | 35,402 | ||
| 2026-01-06 | Christmas Patrick J. Chief Strategy & Legal Officer | Grant or award | +73,749 | 215,367 | ||
| 2026-01-06 | Christmas Patrick J. Chief Strategy & Legal Officer | Grant or award · Stock Options (Right to buy) | +39,650 | 39,650 | ||
| 2026-01-06 | Simpson Curran Chief Executive Officer | Grant or award | +144,864 | 342,467 | ||
| 2026-01-06 | Simpson Curran Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +233,651 | 233,651 | ||
| 2026-01-02 | Malzahn Craig Chief Technology Officer | Shares withheld for taxes | −1,238 | $14.40 | $18K | 16,347 |
| 2026-01-02 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes | −18,247 | $14.40 | $263K | 192,470 |
| 2026-01-02 | Christmas Patrick J. Chief Strategy & Legal Officer | Shares withheld for taxes | −9,793 | $14.40 | $141K | 141,618 |
| 2026-01-02 | Simpson Curran Chief Executive Officer | Shares withheld for taxes | −18,559 | $14.40 | $267K | 197,603 |
Page 3 of 11 · 216 trades